The startup employs microbiome analysis to assess the interactions between gut bacteria and pharmaceuticals, enabling personalized drug efficacy evaluations for individual patients. This method provides specific insights into how a patient's unique microbiome profile influences their response to medications.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current therapeutics often exhibit variable efficacy due to the complex interactions between drugs and the unique bacterial composition within individuals. This variability poses a significant challenge in treating life-changing diseases, as a one-size-fits-all approach often leads to unpredictable outcomes. A deeper understanding of these interactions is needed to improve drug development and personalize treatment strategies.
Solution
BioCorteX leverages microbiome analysis and a proprietary foundational emulator, Carbon Mirror, to predict drug efficacy based on an individual's unique gut bacteria. Built upon Carbon Knowledge, a comprehensive biology-based knowledge graph, Carbon Mirror uncovers hidden interactions between bacteria, the human immune system, diseases, and pharmaceutical interventions. By considering the direct effect of drug-bacteria metabolism, the indirect effect of bacteria on host physiology, and local effects in specific tissues, BioCorteX provides insights into how a patient's microbiome profile influences their response to medications. This approach enables a more personalized and effective drug development process, ultimately improving clinical trial success and treatment outcomes.
Target Audience
The primary audience includes pharmaceutical companies, researchers, and clinicians involved in drug discovery and development, particularly those focused on oncology and personalized medicine.
Features
- Carbon Knowledge: An extensive knowledge graph of microbiome samples from diverse populations worldwide.
- Carbon Mirror: A foundational emulator that uncovers hidden interactions between bacteria, the human immune system, diseases, and pharmaceutical interventions.
- Unified Biology Approach: Considers the full range of high dimensions in biological data to identify gaps in disease understanding.
- Scalable Technology Platform: Enables scientists and clinicians to design hypotheses and deliver results rapidly.
- BigQuery Integration: Stores and analyzes the knowledge graph with over 3 billion nodes and 16 billion edges.
- ADC Analysis: Identifies bacterial proteins that interfere with ADC binding to improve clinical trial outcomes.